The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGF[beta]-induced pulmonary fibrosis

• Published in: British journal of pharmacology 2015-08, Vol.172 (16), p.4173
• Main Authors: Abdalla, Maha, Sabbineni, Harika, Prakash, Roshini, Ergul, Adviye, Fagan, Susan C, Somanath, Payaningal R
• Format: Article
• Language: English
• Subjects: Hypoxia; Lung diseases; Pulmonary fibrosis; Rodents
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1111/bph.13203

Background and Purpose Interstitial lung disease accounts for a group of chronic and progressive disorders associated with severe pulmonary vascular remodelling, peripheral vascular rarefaction and fibrosis, thus limiting lung function. We have previously shown that Akt is necessary for myofibroblast differentiation, a critical event in organ fibrosis. However, the contributory role of the Akt-mTOR pathway in interstitial lung disease and the therapeutic benefits of targeting Akt and mTOR remain unclear. Experimental Approach We investigated the role of the Akt-mTOR pathway and its downstream molecular mechanisms in chronic hypoxia- and TGF[beta]-induced pulmonary vascular pruning and fibrosis in mice. We also determined the therapeutic benefits of the Akt inhibitor triciribine and the mTOR inhibitor rapamycin for the treatment of pulmonary fibrosis in mice. Key Results Akt1-/- mice were protected from chronic hypoxia-induced peripheral vascular pruning. In contrast, hyperactivation of Akt1 induced focal fibrosis similar to TGF[beta]-induced fibrosis. Pharmacological inhibition of Akt, but not the Akt substrate mTOR, inhibited hypoxia- and TGF[beta]-induced pulmonary vascular rarefaction and fibrosis. Mechanistically, we found that Akt1 modulates pulmonary remodelling via regulation of thrombospondin1 (TSP1) expression. Hypoxic Akt1-/- mice lungs expressed less TSP1. Moreover, TSP1-/- mice were resistant to adMyrAkt1-induced pulmonary fibrosis. Conclusions and Implications Our study identified Akt1 as a novel target for the treatment of interstitial lung disease and provides preclinical data on the potential benefits of the Akt inhibitor triciribine for the treatment of interstitial lung disease.